Clinically, while BRAF-mutated tumors have been associated with increased POMC transcription and ACTH secretion, there is currently limited data on their phenotype, including tumor size, invasiveness, or treatment response, due to the rarity of these mutations. The gene discussed is BRAF; the disease is neoplasm.